NCT00611923View on ClinicalTrials.gov

Effectiveness of Flutamide in Treating Women With Premenstrual Dysphoric Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

June 30, 2011

Study Completion Date

December 31, 2011

Conditions
Premenstrual Syndrome
Interventions
DRUG

Flutamide

Participants will take one 125-mg flutamide capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.

DRUG

Placebo

Participants will take a lactose capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Weill Medical College of Cornell University

OTHER

NCT00611923 - Effectiveness of Flutamide in Treating Women With Premenstrual Dysphoric Disorder | Biotech Hunter | Biotech Hunter